Ozempic pill refers to the U.S. oral semaglutide presentation offered as 1.5 mg, 4 mg and 9 mg tablets. FDA first approved this newer higher-bioavailability oral formulation under the Rybelsus application in December 2024; in February 2026 FDA approved the Ozempic name for those tablet strengths, and Novo Nordisk announced availability under that name beginning May 4, 2026. This distinction between the formulation approval and its later rebranding matters when interpreting older FDA records.
Although the Ozempic tablet and Ozempic injection contain semaglutide, they differ in route, strengths, product instructions and certain labeled uses. The oral product also replaced an older formulation historically sold under the Rybelsus name in the U.S.; legacy Rybelsus tablets had 3 mg, 7 mg and 14 mg strengths. A change in milligram numbers reflects formulation differences and must not become a self-directed dose conversion.
This page identifies Ozempic tablets, their label, prescription and packaging context. For the actual tablet transaction, use the Ozempic pill buying checklist; for the broader brand family, use Ozempic overview. For a full practical comparison with injections, see Ozempic tablet versus pen.
The oral semaglutide R2 formulation with 1.5 mg, 4 mg and 9 mg tablets received FDA approval in December 2024, initially as a newer Rybelsus presentation. The February 2026 Ozempic name approval and May 2026 launch did not mean that semaglutide tablets were invented or first evaluated that year. FDA application NDA 213051 provides the continuity between the older brand and the updated oral product.
Compared with the older 3 mg, 7 mg and 14 mg Rybelsus R1 tablets, the updated formula has different oral bioavailability and strength labels. FDA-authorized labeling establishes permitted relationships between the two oral formulations, but patients should not invent a cross-formulation regimen or replace oral tablets with weekly pens by matching numbers.
Ozempic tablets are labeled as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The FDA-approved oral product is also indicated to reduce risk of major adverse cardiovascular events—cardiovascular death, nonfatal heart attack or nonfatal stroke—in certain adults with type 2 diabetes who are at high risk. This is not approval of Ozempic tablets specifically as the Wegovy weight-management pill.
Do not transfer every Ozempic injection benefit onto the tablets: injection-specific labeling includes reduction of certain kidney disease risks in adults with type 2 diabetes and chronic kidney disease. The exact product and indication should be verified against its own label rather than described as “all Ozempic uses.”
Ozempic tablets, legacy Rybelsus tablets and Wegovy tablets are three relevant but distinct retail identities. They have different strengths, indications or transition status. The presence of the same active ingredient does not mean a patient can replace one tablet bottle with another on their own.
The table helps distinguish product identity before any pharmacy inquiry. It is not a clinical conversion chart, a substitution authorization, or a substitute for the prescribed label.
| Product | Relevant U.S. strength context | Labeled purpose / status | Correct next page |
|---|---|---|---|
| Ozempic tablets | 1.5 mg / 4 mg / 9 mg | Current adult type 2 diabetes oral formulation | Tablet purchase: guide |
| Former Rybelsus tablets | 3 mg / 7 mg / 14 mg | U.S. wholesale phase-out during 2026 | History: transition |
| Wegovy tablets | 1.5 mg / 4 mg / 9 mg / 25 mg | Distinct adult weight-management/CV product | Product: Wegovy pill |
| Ozempic injection | Different pen-specific strengths | Weekly injection with form-specific diabetes-related labels | Brand: Ozempic |
Ozempic tablets must be taken according to their own FDA Medication Guide and prescribing information. The approved carton instructs taking the tablet on an empty stomach when first waking, with no more than 4 ounces of plain water, and waiting at least 30 minutes before food, drinks or other oral medicines. The tablet must be swallowed whole rather than split, crushed or chewed.
The product should remain in its original closed bottle until it is taken, protecting it from moisture. These requirements are not generic instructions for every oral weight-management medicine or for Ozempic injection. A pharmacist can review the actual supplied carton with a patient before the first fill.
A licensed U.S. pharmacy should be able to identify the prescribed Ozempic tablets by FDA-labeled strength, package and manufacturer information, and should require a valid prescription. A seller advertising “oral semaglutide” without disclosing whether the item is approved Ozempic is not supplying enough information to evaluate the offer.
Tablets generally have different storage and shipping considerations from temperature-sensitive injection pens. Ask the dispenser about official labeled storage and any applicable dispensing quantity rather than assume pen handling rules apply. The online pharmacy verification guide explains how to confirm the actual licensed dispenser.
An older Rybelsus 3/7/14 mg bottle and the updated 1.5/4/9 mg Ozempic tablets are different finished product presentations within the oral semaglutide history. FDA records from 2024–2026 explain how the newer formulation was approved and later renamed; a storefront displaying a familiar ingredient does not authorize a pharmacy to substitute a product or rewrite the patient’s directions on its own.
People holding an existing Rybelsus prescription should ask their prescriber or pharmacist how to manage the transition and whether a new prescription is needed. Changes in formularies, package identifiers and dispensing records can also affect coverage. The Rybelsus transition reference keeps this historical question separate from current Ozempic product identity.
An oral option avoids injection but requires consistency with oral administration rules; a once-weekly pen uses a different route and device. Both can be discussed in type 2 diabetes care, but the chosen product depends on clinical indication, comorbidities, contraindications, tolerability, other medicines and availability under a legitimate pharmacy route.
Rather than placing an unsupported “better” label on one formulation, consult the dedicated route comparison for daily versus weekly practical issues. Any change in treatment requires a clinician-issued order as appropriate.
Ozempic tablets carry important warnings associated with semaglutide, including the boxed warning for thyroid C-cell tumors seen in rodents and contraindications for personal or family history of medullary thyroid carcinoma or MEN 2. Other precautions include pancreatitis, gallbladder events, gastrointestinal reactions, kidney injury related to dehydration and hypoglycemia in certain combination treatments.
Pregnancy intentions, gastrointestinal history and concomitant oral medications may influence clinical suitability. Do not assume swallowing a tablet makes semaglutide free from systemic effects or monitoring requirements. Seek professional guidance for concerning symptoms.
The oral product has its own prescription and pharmacy claim identity. An insurer may have a different prior-authorization or formulary process for tablets compared with injection, and a manufacturer offer may impose eligibility conditions. Any publicly advertised introductory price should not be mistaken for a guaranteed patient amount.
For tablet-specific purchase logistics use the Ozempic tablet buying guide. For drug-only pricing methodology use Ozempic price, and for insurer requirements use Ozempic insurance coverage.
The FDA-approved Ozempic tablet is a defined finished prescription product. Imported semaglutide brands, compounded mixtures and oral capsules advertised by unrelated sellers are not automatically U.S.-approved generic Ozempic products. Product approval, dosage form, source and dispensing authorization must be confirmed separately.
If a seller claims FDA approval because an ingredient appears on a drug list, review generic semaglutide status and imported-product restrictions rather than relying on a marketplace description.
Look at the exact prescription name, oral dosage form, strength, quantity and current pharmacy label, and ask whether the dispensed bottle is the new Ozempic tablet presentation. The active ingredient name alone is insufficient because Wegovy tablets and discontinued legacy oral products also contain semaglutide. Pharmacies should be able to resolve product identity using official dispensing records.
If you have an older Rybelsus order, seek a new clinically appropriate Ozempic tablet prescription rather than accepting an automatic conversion. If a seller offers an oral capsule or an unidentified overseas product instead, stop and verify the approved source and the actual licensed dispenser.
An oral product may appear simpler than injection, but consistency with fasting-related administration instructions is relevant to its absorption. Before choosing oral semaglutide, a clinician or pharmacist can explain how the labeled conditions fit around existing medicines and the patient’s morning routine. Those questions are particularly useful when other daily oral drugs are taken.
Patients should also understand what constitutes a missed dose, what the product-specific label says about administration and whom to contact for concerning side effects. The right discussion is about the approved product’s instructions, not a do-it-yourself adjustment of frequency or tablet strength.
For the Ozempic oral product, useful primary records include FDA NDA 213051, the February 2026 supplemental name approval, the approved carton and Medication Guide, and Novo Nordisk’s May 2026 availability announcement. These documents support the identity, instructions and authorization dates; they do not establish what a particular U.S. pharmacy has in stock.
Keep manufacturer marketing statements and the authoritative FDA label in their appropriate roles. The FDA-approved tablet indication and directions are the regulatory basis, while insurer coverage, wholesale product transitions and advertised self-pay terms require their own current checks.
Yes. The 1.5, 4 and 9 mg oral formulation was approved under the Rybelsus application in 2024, received the Ozempic name in February 2026 and launched under that name in May 2026.
Ozempic tablets are labeled for adult type 2 diabetes and specified cardiovascular risk reduction, not the same weight-management indication as Wegovy tablets.
No. Even when some numerical strengths overlap, branded labels, intended indications and treatment regimens differ. A prescription cannot be swapped based on milligram number alone.
Not automatically. They are different dosage forms with separate strengths, instructions and certain different indications; a clinician must direct any switch.
The newer oral semaglutide formulation has different bioavailability and lower numeric strength labels. Patients need an appropriate new prescription.
No. FDA-approved oral Ozempic is a prescription medicine in the United States.
Yes. Their labeled uses include improving glycemic control in adults with type 2 diabetes and reducing specified major cardiovascular events in eligible high-risk adults.
Do not assume the forms share storage rules. Check the current tablet label and pharmacy instructions for handling the prescribed product.
Do not assume that such products are FDA-approved Ozempic equivalents. Verify the approved product identity and lawful licensed U.S. dispensing.